Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis
A phase 4 trial registered on ClinicalTrials.gov. The registry status is terminated. It enrolled 321 participants.
Also called NCT03062319
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 4
- Enrolled
- 321 participants
- Sponsor
- National Hospital Organization Osaka National Hospital
- Registry
-
NCT03062319
-
- Other papers using this trial's data
- Optimal Antithrombotics for Ischemic Stroke and Concurrent Atrial Fibrillation and Atherosclerosis: A Randomized Clinical Trial
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Japan
- Registry status
- Terminated
Technical summary
Registry record NCT03062319. Randomized; no masking; primary purpose prevention. Start 2017-04-06 (actual); primary completion 2023-07-18 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Optimal Antithrombotic Therapy in Ischemic Stroke Patients with Non-Valvular Atrial Fibrillation and Atherothrombosis
- Acronym
- ATIS-NVAF
- Condition
- Ischemic Stroke
- Condition
- Atrial Fibrillation
- Condition
- Atherothrombosis
- Intervention (Drug)
- Oral Anticoagulant
- Intervention (Drug)
- Antiplatelet Drug
- Lead sponsor
- National Hospital Organization Osaka National Hospital
- Collaborator
- Network for Clinical Stroke Trials
- Collaborator
- The BMS/Pfizer Japan Thrombosis Investigator Initiated Research Program
Record details
- Record id
cardio:ct-nct03062319- Content hash
370fe4bb52dc92cbfc49a3a6dbb21c088a875a32465d4e071e993bb16b366e02